BioLineRx Ltd. (NASDAQ:BLRX) has been assigned a $3.00 target price by Maxim Group in a note issued to investors on Tuesday. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Maxim Group’s price objective points to a potential upside of 154.24% from the stock’s current price.

BLRX has been the topic of several other reports. Zacks Investment Research upgraded BioLineRx from a “hold” rating to a “buy” rating and set a $1.00 target price on the stock in a research note on Friday, April 21st. HC Wainwright set a $4.00 target price on BioLineRx and gave the stock a “buy” rating in a research note on Tuesday, April 18th. Oppenheimer Holdings, Inc. began coverage on BioLineRx in a research note on Friday. They set an “outperform” rating and a $3.00 target price on the stock. Roth Capital began coverage on BioLineRx in a research note on Thursday, August 3rd. They set a “buy” rating and a $3.00 target price on the stock. Finally, ValuEngine upgraded BioLineRx from a “sell” rating to a “hold” rating in a research note on Monday, July 17th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $2.59.

BioLineRx (BLRX) traded up 3.51% during midday trading on Tuesday, hitting $1.18. The company had a trading volume of 1,123,323 shares. BioLineRx has a 52 week low of $0.79 and a 52 week high of $1.42. The stock’s market capitalization is $72.90 million. The stock has a 50 day moving average price of $0.91 and a 200-day moving average price of $0.96.

BioLineRx (NASDAQ:BLRX) last released its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.05) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.05). On average, equities analysts predict that BioLineRx will post ($0.25) EPS for the current year.

TRADEMARK VIOLATION WARNING: This story was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US & international trademark & copyright laws. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/08/08/biolinerx-ltd-blrx-pt-set-at-3-00-by-maxim-group.html.

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Citadel Advisors LLC increased its stake in BioLineRx by 443.4% in the first quarter. Citadel Advisors LLC now owns 105,986 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 86,481 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in BioLineRx during the first quarter valued at about $126,000. Benchmark Capital Advisors increased its stake in BioLineRx by 227.3% in the first quarter. Benchmark Capital Advisors now owns 144,000 shares of the biotechnology company’s stock valued at $138,000 after buying an additional 100,000 shares during the last quarter. KCG Holdings Inc. increased its stake in BioLineRx by 715.9% in the first quarter. KCG Holdings Inc. now owns 175,156 shares of the biotechnology company’s stock valued at $168,000 after buying an additional 153,687 shares during the last quarter. Finally, Sabby Management LLC acquired a new stake in BioLineRx during the first quarter valued at about $3,018,000. Hedge funds and other institutional investors own 34.91% of the company’s stock.

BioLineRx Company Profile

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.

Analyst Recommendations for BioLineRx (NASDAQ:BLRX)

Receive News & Stock Ratings for BioLineRx Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx Ltd. and related stocks with our FREE daily email newsletter.